Jittima Weerachayaphorn1, Yuhuan Luo2, Albert Mennone2, Carol J Soroka2, Kathy Harry2, James L Boyer3. 1. Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA; Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand. 2. Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA. 3. Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA. Electronic address: james.boyer@yale.edu.
Abstract
BACKGROUND & AIMS: Oltipraz (4-methyl-5(pyrazinyl-2)-1-2-dithiole-3-thione), a promising cancer preventive agent, has an antioxidative activity and ability to enhance glutathione biosynthesis, phase II detoxification enzymes and multidrug resistance-associated protein-mediated efflux transporters. Oltipraz can protect against hepatotoxicity caused by carbon tetrachloride, acetaminophen and alpha-naphthylisothiocyanate. Whether oltipraz has hepato-protective effects on obstructive cholestasis is unknown. METHODS: We administered oltipraz to mice for 5 days prior to bile duct ligation (BDL) for 3 days. Liver histology, liver function markers, bile flow rates and hepatic expression of profibrogenic genes were evaluated. RESULTS: Mice pretreated with oltipraz prior to BDL demonstrated higher levels of serum aminotransferases and more severe liver damage than in control mice. Higher bile flow and glutathione secretion rates were observed in unoperated mice treated with oltipraz than in control mice, suggesting that liver necrosis in oltipraz-treated BDL mice may be related partially to increased bile-acid independent flow and biliary pressure. Oltipraz treatment in BDL mice enhanced α-smooth muscle actin expression, consistent with activation of hepatic stellate cells and portal fibroblasts. Matrix metalloproteinases (Mmp) 9 and 13 and tissue inhibitors of metalloproteinases (Timp) 1 and 2 levels were increased in the oltipraz-treated BDL group, suggesting that the secondary phase of liver injury induced by oltipraz might be due to excessive Mmp and Timp secretions, which induce remodeling of the extracellular matrix. CONCLUSIONS: Oltipraz treatment exacerbates the severity of liver injury following BDL and should be avoided as therapy for extrahepatic cholestatic disorders due to bile duct obstruction.
BACKGROUND & AIMS:Oltipraz (4-methyl-5(pyrazinyl-2)-1-2-dithiole-3-thione), a promising cancer preventive agent, has an antioxidative activity and ability to enhance glutathione biosynthesis, phase II detoxification enzymes and multidrug resistance-associated protein-mediated efflux transporters. Oltipraz can protect against hepatotoxicity caused by carbon tetrachloride, acetaminophen and alpha-naphthylisothiocyanate. Whether oltipraz has hepato-protective effects on obstructive cholestasis is unknown. METHODS: We administered oltipraz to mice for 5 days prior to bile duct ligation (BDL) for 3 days. Liver histology, liver function markers, bile flow rates and hepatic expression of profibrogenic genes were evaluated. RESULTS:Mice pretreated with oltipraz prior to BDL demonstrated higher levels of serum aminotransferases and more severe liver damage than in control mice. Higher bile flow and glutathione secretion rates were observed in unoperated mice treated with oltipraz than in control mice, suggesting that liver necrosis in oltipraz-treated BDLmice may be related partially to increased bile-acid independent flow and biliary pressure. Oltipraz treatment in BDLmice enhanced α-smooth muscle actin expression, consistent with activation of hepatic stellate cells and portal fibroblasts. Matrix metalloproteinases (Mmp) 9 and 13 and tissue inhibitors of metalloproteinases (Timp) 1 and 2 levels were increased in the oltipraz-treated BDL group, suggesting that the secondary phase of liver injury induced by oltipraz might be due to excessive Mmp and Timp secretions, which induce remodeling of the extracellular matrix. CONCLUSIONS:Oltipraz treatment exacerbates the severity of liver injury following BDL and should be avoided as therapy for extrahepatic cholestatic disorders due to bile duct obstruction.
Authors: Wei Wang; Carol J Soroka; Albert Mennone; Christoph Rahner; Kathy Harry; Marc Pypaert; James L Boyer Journal: Gastroenterology Date: 2006-09 Impact factor: 22.682
Authors: Man Li; Wei Wang; Carol J Soroka; Albert Mennone; Kathy Harry; Edward J Weinman; James L Boyer Journal: J Biol Chem Date: 2010-04-19 Impact factor: 5.157
Authors: Angelika F Winkel; Christian K Engel; Daniel Margerie; Aimo Kannt; Hauke Szillat; Heiner Glombik; Christopher Kallus; Sven Ruf; Stefan Güssregen; Jens Riedel; Andreas W Herling; Andreas von Knethen; Andreas Weigert; Bernhard Brüne; Dieter Schmoll Journal: J Biol Chem Date: 2015-10-12 Impact factor: 5.157
Authors: Sebastian Brachs; Angelika F Winkel; James Polack; Hui Tang; Maria Brachs; Daniel Margerie; Bodo Brunner; Kerstin Jahn-Hofmann; Hartmut Ruetten; Joachim Spranger; Dieter Schmoll Journal: PLoS One Date: 2016-11-04 Impact factor: 3.240
Authors: Andrea Ferrigno; Giuseppina Palladini; Alberto Bianchi; Vittoria Rizzo; Laura G Di Pasqua; Stefano Perlini; Plinio Richelmi; Mariapia Vairetti Journal: Biomed Res Int Date: 2014-06-12 Impact factor: 3.411